| The Ministry of Health, the Regions, and AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 간
> 간 질환: 대부분의 유형 | 규제 파트너십
> 규제 기관과의 협력 | 10,000 | National | Regularly | 115023591745 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 규제 파트너십
> 규제 기관과의 협력 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 희귀
> 희귀 질환: 대사/리소좀 | 규제 파트너십
> 규제 기관과의 협력 | 1,000 | National | Regularly | 115050896715 |
| Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services], Ministry of Health, Lazio Region. | 호흡기
> 호흡기: 대부분의 상태 | 규제 파트너십
> 규제 기관과의 협력 | 5,000 | National | Sometimes | 115052531440 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 규제 기관과의 협력 | 100,000 | National | Regularly | 115057561938 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 규제 기관과의 협력 | 100,000 | National | Regularly | 115057561938 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 하트
> 심부전 | 규제 파트너십
> 규제 기관과의 협력 | 10,000 | National | Regularly | 115057865983 |
| Approval of medicinal products by AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 호흡기
> 폐동맥 고혈압 | 규제 파트너십
> 규제 기관과의 협력 | 100 | National | Rarely | 115060569246 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 신장
> 신장 질환 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 1,000 | Regional | Sometimes | 114997535217 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 면역
> 원발성 면역결핍증 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 10,000 | National | Regularly | 115020417471 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 암
> 암: 유방 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | We do not communicate with patients directly | National | Sometimes | 115035044046 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products. | 희귀
> 희귀 질환: 신장 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100 | National | Rarely | 115057369547 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 100,000 | National | Regularly | 115057561938 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 희귀
> 희귀 질환: 유전성 | 규제 파트너십
> 마케팅 허가 제출에 기여 | 100,000 | International | Regularly | 119078073632 |
| Our regional representatives participate in the regional diabetes technical working groups. | 내분비
> 당뇨병(1형 및 2형 모두) | 규제 파트너십
> 임상 지침 설정 기관과의 관계 | 10,000 | National | No | 115028521635 |
| We requested meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] on two occasions; one such request, in 2023, was successful. | 암
> 암: 담관 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100,000 | National | Rarely | 114996625156 |
| Meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and Agenas [Agenzia Nazionale per i Servizi Sanitari Regionali – National Agency for Regional Health Services]. | 신장
> 신장 질환 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | Regional | Sometimes | 114997535217 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 출혈
> 출혈 장애: 대부분의 유형 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 희귀
> 낭포성 섬유증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Regularly | 115005109524 |
| Through the Ministry of Health and the Lombardy Region. | HIV
> HIV | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | Local | Regularly | 115006694528 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], CNS [Consiglio Nazionale della Sanità - National Health Council], the Ministry, Parliament, the Regions, and regulatory bodies. | 면역
> 원발성 면역결핍증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Regularly | 115020417471 |
| We engage in dialogue with the Regional Authority and with the ASP [Aziende Sanitarie Provinciali – Provincial Health Authorities]. | 출혈
> 혈우병 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100 | Regional | Regularly | 115037242647 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 내분비
> 당뇨병(1형 및 2형 모두) | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency]. | 신경학적
> 다발성 경화증 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100,000 | National | Regularly | 115038849633 |
| Through submissions to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] via the Technical Health Committee of the Ministry of Health. | HIV
> HIV | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | National | Regularly | 115050875230 |
| The organisation represents patients before national and European regulatory bodies, including AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and EMA [European Medicines Agency]. | 희귀
> 희귀 질환: 대사/리소좀 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 1,000 | National | Regularly | 115050896715 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100,000 | National | Regularly | 115057561938 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 희귀
> 희귀 질환: 간 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 100 | National | Rarely | 115057832320 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 하트
> 심부전 | 규제 파트너십
> 정책 입안자/규제 기관과의 회의 참석/진행 | 10,000 | National | Regularly | 115057865983 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition. | 암
> 암: 혈액 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 1,000 | National | Rarely | 115006753491 |
| Through the UNIAMO [Unione Italiana delle Associazioni di Malati – Italian Federation of Rare Disease Patient Organisations] Federation, with which we are affiliated. | 희귀
> 희귀 질환: 대부분의 유형 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | National | Regularly | 115055436186 |
| Through a network of associations. | 암
> 암: 대부분의 유형 | 규제 파트너십
> 다른 의료 지지자들과 함께 | 100 | National | Regularly | 115057092350 |
| We are actively campaigning for the amendment or abolition of Nota 99 [Nota 99 is the Italian Medicines Agency (AIFA) reimbursement guideline for Chronic Obstructive Pulmonary Disease (COPD) maintenance therapies. It regulates the prescription of inhalers, ensuring appropriate diagnosis through spirometry while detailing which treatments GPs can initiate or repeat]. We are also campaigning for vaccination against Respiratory Syncytial Virus (RSV). | 호흡기
> 천식 및 COPD | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 5,000 | National | Regularly | 114996865765 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 일반 건강
> 비만 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 10,000 | National | Regularly | 115012927513 |
| Cardiovascular Alliance — Ministry of Health. | 심혈관
> 심혈관: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 100 | Regional | Sometimes | 115028352096 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 뼈
> 뼈: 기타 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 100 | National | Regularly | 115037246562 |
| Yes. The association represents patients' interests before the institutions and regulatory authorities involved in decision-making processes related to healthcare policy, access to therapies, and the sustainability of the healthcare system. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 100,000 | National | Regularly | 115057561938 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 뼈
> 뼈: 기타 | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100 | National | Regularly | 115037246562 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 내분비
> 당뇨병(1형 및 2형 모두) | 정책 및 법률에 영향 미치기
> 공청회 및 협의에 참여하기 | 100 | Local | Sometimes | 115037371533 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 신경학적
> 다발성 경화증 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 100,000 | National | Regularly | 115038849633 |
| Cross-Party Parliamentary Group — IVT [Intravitreal Therapy] Technical Working Group. Cataract Technical Working Group — Regional Partnerships — Local Activities. | 시각 장애
> 시각 장애 | 정책 및 법률에 영향 미치기
> 의회 의원 및 정치 지도자 동원 | 1,000 | National | Regularly | 115056238448 |
| Active participation in the drafting and approval of legislation in support of the disease area. | 일반 건강
> 비만 | 정책 및 법률에 영향 미치기
> 공중 보건 법률 초안 작성에 기여 | 10,000 | National | Regularly | 115012927513 |
| AISC [Associazione Italiana Scompensati Cardiaci – Italian Association of Heart Failure Patients] maintains frequent engagement with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] and with national and regional decision-makers regarding the introduction and adoption of new medicinal products in cardiovascular diseases. | 하트
> 심부전 | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 10,000 | National | Regularly | 115057865983 |
| Market authorisation for "Koselugo" [used to treat neurofibromatosis type 1 (NF1)] should be extended to adult patients, given that it is currently approved only for paediatric cases where surgery is not an option. | 신경학적
> 신경섬유종증(NF) | 정책 및 법률에 영향 미치기
> 의료 서비스의 장벽/이상 현상 해결 | 1,000 | National | Sometimes | 115060431887 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 지정되지 않음
> 지정되지 않음 | 가격 책정 및 affordability 옹호
> 의약품 가격/의약품 부족 현황 추적 및 모니터링 | 100 | Local | Regularly | 115037563159 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 내분비
> 당뇨병(1형 및 2형 모두) | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 1,000 | Local | Sometimes | 115023236354 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 내분비
> 당뇨병(1형 및 2형 모두) | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100 | Local | Sometimes | 115037371533 |
| Our work focuses on securing reimbursement for medicines, not on pricing. | 신경퇴행성
> 치매 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 100,000 | National | Rarely | 115060441597 |
| Organisation of educational camps, disease prevention, regulatory-compliant monitoring [in Italy], and waiting list management. | 지정되지 않음
> 지정되지 않음 | 가격 책정 및 affordability 옹호
> 인식 제고 캠페인 참여 | 100 | Local | Regularly | 115037563159 |
| Competitive tender for diabetes medical devices and supplies. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Regional | Rarely | 114997517950 |
| We request meetings with regional authorities and hospital management bodies responsible for pharmaceutical distribution. | 출혈
> 출혈 장애: 대부분의 유형 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100 | Regional | Sometimes | 114997584898 |
| Through meetings with AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] to safeguard the continued availability of medicines. | 희귀
> 낭포성 섬유증 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 10,000 | National | Regularly | 115005109524 |
| We collaborate with other patient associations of a similar nature to advocate for the approval and release of medicines required for our condition [blood cancers]. | 암
> 암: 혈액 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Rarely | 115006753491 |
| Extension of the indications for the use of Baqsimi, indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged one year and above with diabetes mellitus. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Regional | Sometimes | 115021346889 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Local | Sometimes | 115023236354 |
| At the regional health authority level in particular, advocacy efforts were undertaken to extend the prescribability of Baqsimi (nasal glucagon) to include reimbursement for adult patients with diabetes. Additionally, participation in the competitive tendering process for diabetes medical devices and supplies — including reagent test strips, continuous glucose monitoring sensors, and insulin pumps — was pursued. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 시각 장애
> 시신경척수염 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100 | National | Regularly | 115024933081 |
| Meetings with FG [Focus Group] to improve community-based diabetology services. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100 | Local | Sometimes | 115032223368 |
| We are seeking early access for the drug vorasidenib [oral cancer therapy for people with gliomas]. | 암
> 암: 뇌 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100 | National | Sometimes | 115050882510 |
| Formal request letters to expedite access to medicines. | 암
> 암: 부인과 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Sometimes | 115055638865 |
| The association represents patient interests before the institutions and regulatory authorities involved in decision-making processes relating to health policy, access to therapies, and the sustainability of the healthcare system. In particular, it promotes dialogue with regulatory bodies, healthcare institutions, and health system stakeholders with the aim of contributing to the development of policies that ensure equitable and appropriate access to treatments for people living with rheumatological conditions. This encompasses direct engagement with AIFA [Agenzia Italiana del Farmaco — the Italian Medicines Agency], as well as with regional authorities where dedicated regional working groups on rheumatological and rare rheumatological diseases have been established. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 100,000 | National | Regularly | 115057561938 |
| AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] or regional health authorities regarding delays in the market access of medicines. | 암
> 암: 부인과 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | National | Rarely | 115060470442 |
| We are campaigning for vaccination against Respiratory Syncytial Virus (RSV) [in Italy]. | 호흡기
> 천식 및 COPD | 접근 경로 개선
> 더 넓은 백신 접근성을 위해 옹호하기 | 5,000 | National | Regularly | 114996865765 |
| Specifically at the level of the regional health authority, we have engaged in advocacy for the extension of the prescribability of Baqsimi (nasal glucagon) to be also reimbursable for adult diabetic patients. | 내분비
> 당뇨병(1형 및 2형 모두) | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 1,000 | Local | Sometimes | 115023236354 |
| The association is at the forefront of efforts to ensure that all patients receive the appropriate therapy and that treatment is applied consistently at the national level. | 시각 장애
> 시신경척수염 | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 100 | National | Regularly | 115024933081 |
| We are an integral part of the Innovative Medicines Group of the Veneto Region [part of Veneto Region's governance structure for evaluating and managing access to innovative medicines]. | 암
> 암: 혈액 | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 1,000 | National | Regularly | 115053421236 |
| Regional disparities in access to treatment and enrolment in therapeutic management plans. | 신경학적
> 간질 | 접근 경로 개선
> 접근성 및 관리의 불균형 해소 | 1,000 | Regional | Sometimes | 115063172483 |
| By participating in regional and national policy-setting forums on rare diseases and skeletal dysplasia conditions more broadly. | 뼈
> 뼈: 기타 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | National | Regularly | 115037246562 |
| Letters were co-authored and submitted to AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency] at the request of paediatric nephrologists, seeking compassionate use authorisation for investigational medicinal products [for rare kidney conditions]. | 희귀
> 희귀 질환: 신장 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | National | Rarely | 115057369547 |
| The organisation [in Italy] actively engaged in challenging the withdrawal of a marketing authorisation for a medicinal product. It contributed to the submission of formal representations to the European Commission urging reconsideration of the withdrawal. | 희귀
> 희귀 질환: 간 | 진단 및 의약품 배달
> 안전하고 효과적인 의약품 사용 보장 | 100 | National | Rarely | 115057832320 |
| Our regional representatives participate in the regional diabetes technical working groups. | 내분비
> 당뇨병(1형 및 2형 모두) | 진단 및 의약품 배달
> 임상 지침 개발에 참여 | 10,000 | National | No | 115028521635 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. | 신경학적
> 다발성 경화증 | 진단 및 의약품 배달
> 임상 지침 개발에 참여 | 100,000 | National | Regularly | 115038849633 |
| By participating in the regional coordination body that sits on the regional working table. | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | Regional | Rarely | 115019671886 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100,000 | National | Regularly | 115031446886 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | Local | Regularly | 115037426004 |
| We maintain regular contact with the relevant offices of the Tuscany Regional Authority. | 출혈
> 혈우병 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | Regional | Regularly | 115043798242 |
| Represent patients before national and European regulatory bodies — including AIFA [Agenzia Italiana del Farmaco, the Italian Medicines Agency] and EMA [European Medicines Agency] — as well as national health institutions and local authorities. | 희귀
> 희귀 질환: 대사/리소좀 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 1,000 | National | Regularly | 115050896715 |
| In an advisory capacity, when consulted by the local and regional health authority (Azienda Sanitaria Locale). | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100 | Local | Rarely | 115060756578 |
| We are members of the EMA [European Medicines Agency] multi-stakeholder advisory board, and we are frequently invited to participate in the scientific advice committee for the approval of medicines for mitochondrial diseases. | 희귀
> 희귀 질환: 유전성 | 기관 거버넌스
> 정부 자문 기구 내 대표성 확보 | 100,000 | International | Regularly | 119078073632 |
| By participating in the regional coordination body that sits on the regional working table. | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | Regional | Rarely | 115019671886 |
| Participated alongside Public Institutions in the Stroke Observatory. | 뇌혈관
> 획 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 5,000 | National | Regularly | 115019690819 |
| Participated alongside Public Institutions in the Stroke Observatory. | 뇌혈관
> 획 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 5,000 | National | Regularly | 115019690819 |
| Regional health councillors, prescribing physicians, hospital pharmacists, regional drug directors, and representation at regional stakeholder forums. | 류마티스성
> 류마티스 질환: 대부분의 유형 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100,000 | National | Regularly | 115031446886 |
| Participation in public consultations of AIFA [Agenzia Italiana del Farmaco – Italian Medicines Agency], regional diabetes working groups, and contributions on access to CGM [Continuous Glucose Monitoring sensors sensors], insulin pumps, and innovative medicines. | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | Local | Sometimes | 115037371533 |
| We collaborate with institutional decision-makers, policymakers, and clinicians within a technical working group. | 내분비
> 당뇨병(1형 및 2형 모두) | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100 | Local | Regularly | 115037426004 |
| Audit and relationship with Italian regulatory AIFA [Agenzia Italiana del Farmaco - Italian Medicines Agency]. Relationship with regional health authorities. Reference clinical care pathways. Relationship with Ministries (Health, Welfare, Disability). | 신경학적
> 다발성 경화증 | 기관 거버넌스
> 다중 이해관계자 네트워크 내에서 효과적으로 협력하기 | 100,000 | National | Regularly | 115038849633 |
| Healthcare protection, consumer protection, and other related areas. | 일반 건강
> 의료 서비스 제공 | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | 1,000 | Regional | Regularly | 115038525050 |
| Documentation requirements for the renewal of driving licences for individuals with diabetes. | 내분비
> 당뇨병(1형 및 2형 모두) | 환자 권리 보호/삶의 질 향상
> 환자 경험 보호/개선 | Do not know | Regional | Sometimes | 115046244188 |
상호작용
활동 및 옹호
31 멘션
